# Janagliflozin Treat T2DM Monotherapy

Study · id `cardio:ct-nct03811548` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03811548](<https://clinicaltrials.gov/study/NCT03811548>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03811548

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 442 participants.

## Technical summary

Registry record NCT03811548. Randomized; quadruple masking; primary purpose treatment. Start 2019-05-23 (actual); primary completion 2020-06-24 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 442 participants (planned count; ClinicalTrials.gov record NCT03811548, source copy `cardio:ctgov-nct03811548-2020-07-16`, retrieved 2026-10-26)
- Started: 2019-05-23 (actual) (ClinicalTrials.gov record NCT03811548, source copy `cardio:ctgov-nct03811548-2020-07-16`, retrieved 2026-10-26)
- Primary completion: 2020-06-24 (actual) (ClinicalTrials.gov record NCT03811548, source copy `cardio:ctgov-nct03811548-2020-07-16`, retrieved 2026-10-26)
- Completion: 2020-12-31 (anticipated) (ClinicalTrials.gov record NCT03811548, source copy `cardio:ctgov-nct03811548-2020-07-16`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT03811548, source copy `cardio:ctgov-nct03811548-2020-07-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03811548-2020-07-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Janagliflozin Treat T2DM Monotherapy
- Condition: Diabetes Type 2
- Intervention (Drug): Janagliflozin 25mg
- Intervention (Drug): Janagliflozin 50mg
- Intervention (Drug): Placebo/Janagliflozin
- Lead sponsor: Sihuan Pharmaceutical Holdings Group Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)

## Provenance

Content hash: 7646b3f2417dfc092e5bc992f66a3b7b54af1194397b60f584c8dfa84e8fff73
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
